Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 3
3(50.0%)
Phase 1
2(33.3%)
Phase 2
1(16.7%)
6Total
Phase 3(3)
Phase 1(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT05594927Phase 3Recruiting

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Role: lead

NCT03236649Phase 3Terminated

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Role: lead

NCT01972672Phase 2Completed

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Role: lead

NCT03236636Phase 3Unknown

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Role: lead

NCT02496949Phase 1Completed

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Role: collaborator

NCT01278810Phase 1Unknown

Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients

Role: collaborator

All 6 trials loaded